Company intelligence / Profile preview
ExeVir Bio
Ghent, Flemish Region, Belgiumexevir.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
ExeVir's lead compound XVR013m shows exceptional neutralization potency across both SARS-CoV-2 pre-Omicron and Omicron variants. The company has completed Phase 1a and Phase 1b studies for its first candidate drug with good pharmacodynamics and efficient GMP manufacturability. XVR013m is being developed to start a First in Human clinical trial in 2025.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VHH antibodiesHeavy chain-only antibodiesMulti-specific antibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
VIB
Beyond the preview
Go deeper on ExeVir Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExeVir Bio.